comparison of Pueraria minifica gel and placebo gel effects on vaginal microenvironment among postmenopausal women with genitourinary syndrome of menopause (GSM)

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20160517002

Enrollment

Registered

2016-05-17

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postmenopausal women with genitourinary syndrome of menopause (GSM) Pueraria mirifica

Interventions

extracted gel from Peuraria minifica that is containing of natural estrogen,placebo gel

Experimental Drug,Placebo Comparator Drug

Pueraria minifica,placebo gel

Eligibility

Sex/Gender

Female

Age

50 Years to 70 Years

Inclusion criteria

Inclusion criteria: postmenopausal women with genitourinary syndrome of menopause no history of external hormone used in 3 month

Exclusion criteria

Exclusion criteria: participants who had sexually transmitted diseases, breast or female genital tract malignancy, or had taken any sex hormones within the past three months

Design outcomes

Primary

Measure	Time frame
vaginal flora index 12 weeks nugent score	—

Secondary

Measure	Time frame
ph, gram strain and grading, modified amsell criteria, endometrium thickening 12 weeks PV, TVS, wel smear, gram stain	—

Countries

thailand

Contacts

Public Contactchuleekorn Sritonchai

Ramathibodi hospital

chuleekorn8834@gmail.com0924519949

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026